Statements (16)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:filedForBankruptcy |
2022
|
| gptkbp:focus |
men's health
testosterone replacement therapy |
| gptkbp:founded |
2003
|
| gptkbp:founder |
Robert Dudley
|
| gptkbp:headquartersLocation |
gptkb:Northbrook,_Illinois,_United_States
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:notableProductApproval |
Jatenzo FDA approval 2019
|
| gptkbp:product |
gptkb:Jatenzo
|
| gptkbp:publiclyTraded |
gptkb:NASDAQ:CRXT
|
| gptkbp:type |
gptkb:public_company
|
| gptkbp:website |
https://www.clarustherapeutics.com/
|
| gptkbp:bfsParent |
gptkb:Tommy_Thompson
|
| gptkbp:bfsLayer |
6
|
| https://www.w3.org/2000/01/rdf-schema#label |
Clarus Therapeutics
|